NICE published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD). In 2012, NICE issued guidance that recommended roflumilast only if patients were taking it as part of a research study. New evidence since that guidance was published led to a positive recommendation for routine use. The company estimates that around 122,000…
Our projects
